Praxis Precision Medicines' Share Pullback Represents Good Entry Point, RBC Says

MT Newswires Live06-18

Praxis Precision Medicines' (PRAX) recent share pullback provides investors an "interesting entry point" as the reward/risk proposition of over $7.8 billion in revenue potential by 2035 is attractive, RBC Capital Markets said in a note emailed Thursday.

The investment firm said Praxis' ulixacaltamide, a potential treatment for essential tremor, has a "reasonable likelihood" of reaching more than $4.3 billion in sales.

RBC said that while ulix faces some regulatory risks, checks with experts indicate it can make it to market, where there is a "large unmet need and strong desire to prescribe" among physicians.

Meanwhile, Praxis may also see a "modest opportunity" for its relutrigine potential treatment for genetically driven epilepsy, RBC said, adding that there is a "strong mechanistic rationale and supportive early data."

RBC started coverage of Praxis with an outperform rating and $449 price target.

Praxis shares were up past 2% in morning trading.

Price: 277.86, Change: +7.85, Percent Change: +2.91

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment